Jamie Chung Mei Lam1, Agnes Yuen Kwan Lai1, Terence Chi Chun Tam1, Michele Mae Ann Yuen2, Karen Siu Ling Lam2,3, Mary Sau Man Ip4,5. 1. Division of Respiratory Medicine, University Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong, SAR, China. 2. Division of Endocrinology, University Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong, SAR, China. 3. Research Centre for Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong. 4. Division of Respiratory Medicine, University Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong, SAR, China. msmip@hku.hk. 5. Research Centre for Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong. msmip@hku.hk.
Abstract
PURPOSE:Obstructive sleep apnea (OSA) is highly associated with type 2 diabetes mellitus (DM), and treatment of OSA may have a positive impact on cardiometabolic profile. This study investigates the effects of continuous positive airway pressure (CPAP) treatment on glycemic control and cardiometabolic parameters in patients with diabetes. METHODS:Diabetic patients, who were newly diagnosed of OSA with an apnea hypopnea index (AHI) ≥15 and HbA1c ≥7%, were randomly assigned to either CPAP treatment or no treatment (control) for 3 months. Measurements included HbA1c, blood pressure, fasting glucose and lipids, urinary albumin, and peripheral arterial tonometry (to assess endothelial function). RESULTS:Sixty-four patients (52 men) were randomized, with mean (±SD) age of 55.0 ± 9.6 years, body mass index of 29.9 ± 5.3 kg/m2, HbA1c of 8.1 ± 1.1%, and AHI of 45.3 ± 23.2 events/h. In the intention-to-treat analysis, no significant change in HbA1c but reduction of systolic (10 mmHg (-18 to -2), p < 0.05) and diastolic (6 mmHg (-11 to -1), p < 0.05) blood pressures were found in the CPAP group compared to the control group. Excluding those with medication changes or initiated dietary program during the study period and those who dropped out, CPAP treatment decreased HbA1c (intervention group, n = 27; control group, n = 26) by 0.4% (-0.7 to -0.1), p = 0.027. CONCLUSIONS: In patients with type 2 DM and moderate to severe OSA, 3 months of CPAP therapy did not decrease HbA1c but lowered systolic and diastolic blood pressures. In view of a potentially limited effect size of CPAP treatment on glycemic control, sample size estimation for future randomized controlled studies must make adequate allowance for influence from external factors of medications/diet and CPAP use.
RCT Entities:
PURPOSE: Obstructive sleep apnea (OSA) is highly associated with type 2 diabetes mellitus (DM), and treatment of OSA may have a positive impact on cardiometabolic profile. This study investigates the effects of continuous positive airway pressure (CPAP) treatment on glycemic control and cardiometabolic parameters in patients with diabetes. METHODS:Diabeticpatients, who were newly diagnosed of OSA with an apnea hypopnea index (AHI) ≥15 and HbA1c ≥7%, were randomly assigned to either CPAP treatment or no treatment (control) for 3 months. Measurements included HbA1c, blood pressure, fasting glucose and lipids, urinary albumin, and peripheral arterial tonometry (to assess endothelial function). RESULTS: Sixty-four patients (52 men) were randomized, with mean (±SD) age of 55.0 ± 9.6 years, body mass index of 29.9 ± 5.3 kg/m2, HbA1c of 8.1 ± 1.1%, and AHI of 45.3 ± 23.2 events/h. In the intention-to-treat analysis, no significant change in HbA1c but reduction of systolic (10 mmHg (-18 to -2), p < 0.05) and diastolic (6 mmHg (-11 to -1), p < 0.05) blood pressures were found in the CPAP group compared to the control group. Excluding those with medication changes or initiated dietary program during the study period and those who dropped out, CPAP treatment decreased HbA1c (intervention group, n = 27; control group, n = 26) by 0.4% (-0.7 to -0.1), p = 0.027. CONCLUSIONS: In patients with type 2 DM and moderate to severe OSA, 3 months of CPAP therapy did not decrease HbA1c but lowered systolic and diastolic blood pressures. In view of a potentially limited effect size of CPAP treatment on glycemic control, sample size estimation for future randomized controlled studies must make adequate allowance for influence from external factors of medications/diet and CPAP use.
Authors: Jonathan E Shaw; Naresh M Punjabi; Matthew T Naughton; Leslee Willes; Richard M Bergenstal; Peter A Cistulli; Greg R Fulcher; Glenn N Richards; Paul Z Zimmet Journal: Am J Respir Crit Care Med Date: 2016-08-15 Impact factor: 21.405
Authors: Naomi M Hamburg; Joseph Palmisano; Martin G Larson; Lisa M Sullivan; Birgitta T Lehman; Ramachandran S Vasan; Daniel Levy; Gary F Mitchell; Joseph A Vita; Emelia J Benjamin Journal: Hypertension Date: 2011-01-24 Impact factor: 10.190
Authors: Paul C Myhill; Wendy A Davis; Kirsten E Peters; S A Paul Chubb; David Hillman; Timothy M E Davis Journal: J Clin Endocrinol Metab Date: 2012-09-07 Impact factor: 5.958
Authors: Iskandar Idris; Andrew P Hall; John O'Reilly; Anthony Barnett; Martin Allen; Robert Andrews; Phillipe Grunstein; Keir Lewis; Niru Goenka; John P Wilding Journal: Diabetes Obes Metab Date: 2009-06-07 Impact factor: 6.577
Authors: Terri E Weaver; Greg Maislin; David F Dinges; Thomas Bloxham; Charles F P George; Harly Greenberg; Gihan Kader; Mark Mahowald; Joel Younger; Allan I Pack Journal: Sleep Date: 2007-06 Impact factor: 5.849
Authors: James Patrick Smith; Luke G Cyr; Laura K Dowd; Kyla S Duchin; Priscilla A Lenihan; Jennifer Sprague Journal: Optom Vis Sci Date: 2019-11 Impact factor: 1.973
Authors: Babak Mokhlesi; Ashley H Tjaden; Karla A Temple; Sharon L Edelstein; Susan Sam; Kristen J Nadeau; Tamara S Hannon; Shalini Manchanda; Kieren J Mather; Steven E Kahn; David A Ehrmann; Eve Van Cauter Journal: Diabetes Care Date: 2021-02-05 Impact factor: 19.112
Authors: Mary R Rooney; R Nisha Aurora; Dan Wang; Elizabeth Selvin; Naresh M Punjabi Journal: Contemp Clin Trials Date: 2020-12-11 Impact factor: 2.226
Authors: Urmi Sheth; Rebecca S Monson; Bharati Prasad; Ashima S Sahni; Sara Matani; Tomas Mercado; Maureen A Smith; Melissa A Carlucci; Kirstie K Danielson; Sirimon Reutrakul Journal: J Clin Sleep Med Date: 2021-08-01 Impact factor: 4.324
Authors: Sophie Kobuch; Fiona Tsang; Ritesh Chimoriya; Daniel Gossayn; Sarah O'Brien; Javeria Jamal; Leon Laks; Abd Tahrani; Nic Kormas; Milan K Piya Journal: BMC Endocr Disord Date: 2021-11-14 Impact factor: 2.763